ClinicalTrials.gg
RecruitingNCT05388461Updated Sep 26, 2023

Acute Efficacy and 6 Months Follow up After Electroconvulsive Therapy

An observational study in Depressive Disorder, sponsored by Haukeland University Hospital. Recruiting at 2 sites in Norway. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-09-26.

Sponsored by Haukeland University Hospital · Observational

How we know

From the registry’s dates

  • Started Mar 2013; still recruiting 13 years 8 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
600
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 15 studies in Depressive Disorder with a site in Norway — 4 open to participants now, 5 under way, none of them phase 3. Depressive Disorder · Norway.

Started
2013
with 2 others
Observational
5 of 15
1 open now
Registered
12th of 15
by date
Lead sponsor
1 of 15
Haukeland University Hospital

Among the 15 studies in Depressive Disorder with a site in Norway, this one is one of 3 that started in 2013, is one of 5 observational ones, and was the 12th registered.

Depressive Disorder

857 studies on the registry are indexed under Depressive Disorder; 160 are open to participants now.

Browse Depressive Disorder studies →

Open to participants now

4 of the 15 studies in Depressive Disorder with a site in Norway are open now. Recruiting first, the newest first:

All 4 open studies →

A study can be open while its sites in Norway have not opened yet or have stopped. Only those recruiting at a site in Norway →

Who these studies take

Of the 116 Depressive Disorder studies recruiting now, 44 (38%) set no upper age limit and 66 (57%) stop at 75 or younger; 24 take children under 18; 25 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 15 studies in Depressive Disorder with a site in Norway, or all of them as a file.
02

Study summary

The overall aim of the current project is to assess the acute and long term outcome of ECT (both patient and clinician rated) in a non-selected patient cohort from ordinary clinical activity, and to seek out factors predicting response and remission, side effects and relapse.

Read the detailed description

Patients reffered to electroconvulsive ECT are (after written consent) enroled in a research registry. Based on (clinician and patient rated) measures of depressive symptoms and overall cognitive function, the short and long-term (6 months) efficacy of ECT will be described, and factors predicting response and relapse identified.

The duration of possible cognitive impairment and factors predicting cognitive outcome will be examined.

03

Conditions studied

  • Depressive Disorder

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Probability sample

Study population

population based cohort from ordinary clinical activity

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients treated with ECT for major depression (F31.3-5, F32, F33) at Haukeland University Hospital or Stavanger University Hospital after 2013,
  • written consent to enrolment into the Regional Register for neurostimulation.

Exclusion criteria

Exclusion Criteria:

  • ECT performed on other indications than major depression.
  • No consent to the register.
05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
600 participants (estimated)
Target follow-up
6 Months
Patient registry
Yes

Interventions

  • Otherelectroconvulsive therapy

    electroconvulsive therapy

06

What researchers measure

Primary outcomes

  1. Change of Montgomery and Åsberg Depression Rating Scale (MADRS) score from pretreatment at posttreatment; MADRS range 0 - 60, with higher scores indicating more severe depression)

    depressive symptoms

    Time frame: up to 8 weeks

  2. Change of Mini Mental State Examination (MMSE-NR) score from pretreatment at posttreatment; MMS-E range 0-30 with lower scores indicating more severe cognitive impairment

    overall cognitive function

    Time frame: up to 8 weeks

  3. Change of Beck depression inventory (BDI) score from pretreatment at posttreatment; BDI range 0-63, with higher scores indicating more severe depression

    depressive symptoms, patient rated

    Time frame: up to 8 weeks

  4. Change of Everyday Memory Questionnaire (EMQ) score from pretreatment at posttreatment with higher scores indicating more severe impairment

    overall subjective cognitive function, patient rated

    Time frame: up to 8 weeks

Secondary outcomes

  1. Change of Patient rated improvement (PGI) score from pretreatment at posttreatment

    Likert scale

    Time frame: up to 8 weeks

  2. Change of Clinical Global Impression (CGI) score from pretreatment at posttreatment

    Likert scale

    Time frame: up to 8 weeks

  3. Change of Subjective cognitive function score from pretreatment at posttreatment

    Likert scale

    Time frame: up to 8 weeks

  4. Change of Montgomery and Åsberg Depression Rating Scale (MADRS) score from pretreatment at follow up, MADRS range 0 - 60, with higher scores indicating more severe depression)

    depressive symptoms

    Time frame: 6 months

  5. Change of Mini Mental State Examination (MMSE-NR) score from pretreatment at follow up, MMS-E range 0-30 with lower scores indicating more severe cognitive impairment

    overall cognitive function

    Time frame: 6 months

  6. Change of Beck depression inventory (BDI) score from pretreatment at follow up, BDI range 0-63, with higher scores indicating more severe depression

    depressive symptoms, patient rated

    Time frame: 6 months

  7. Change of Everyday Memory Questionnaire (EMQ) score from pretreatment at follow up

    overall subjective cognitive function, patient rated

    Time frame: 6 months

  8. Change of Patient rated improvement (PGI) score from pretreatment at follow up

    Likert scale

    Time frame: 6 months

  9. Change of Clinical Global Impression scale (CGI) from pretreatment at follow up

    Likert scale

    Time frame: 6 months

07

Study locations

2 of 2 sites recruiting
08

References and documents

Individual participant data

Plan to share: Undecided — after approval from data protection manager IPD will be shared on reasonable request

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Mar 2013 (actual). Primary completion is estimated for Dec 2028, 189 months after the start.

Of 54 non-industry observational studies under Depressive Disorder, half reached primary completion within 39 months of starting (the median), counting those still running; a quarter within 24 and three quarters within 104. This study's planned 189 months is above that.

Counting every sponsor, half of 57 studies reached it within 38 months; a quarter within 21 and three quarters within 104.

How these figures are worked out, and which studies are left out of them.

Registered
May 13, 2022
First posted
May 24, 2022
StartActual
Mar 13, 2013
Primary completionEst.
Dec 2028
CompletionEst.
Dec 2028
Last update
Sep 26, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Sep 26, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05388461
Collaborators
Helse Stavanger HF
Responsible party
Sponsor
First posted
May 24, 2022
Start date
Mar 13, 2013
Primary completion
Dec 2028 (estimated)
Completion
Dec 2028 (estimated)
Last update
Sep 26, 2023

Study contacts

Ute Kessler, PhD
Contact
ute.kessler@helse-bergen.no

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion